Symbols / PALI Stock $1.75 -1.69% Palisade Bio, Inc.
PALI (Stock) Chart
About
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 290.65M |
| Enterprise Value | 161.96M | Income | -16.78M | Sales | — |
| Book/sh | 0.81 | Cash/sh | 0.80 | Dividend Yield | — |
| Payout | 0.00% | Employees | 14 | IPO | — |
| P/E | — | Forward P/E | -6.52 | PEG | — |
| P/S | — | P/B | 2.16 | P/C | — |
| EV/EBITDA | -8.97 | EV/Sales | — | Quick Ratio | 28.83 |
| Current Ratio | 28.95 | Debt/Eq | 0.06 | LT Debt/Eq | — |
| EPS (ttm) | -0.30 | EPS next Y | -0.27 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-10 16:00 | ROA | -15.54% |
| ROE | -24.52% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 165.88M |
| Shs Float | 122.27M | Short Float | 17.55% | Short Ratio | 8.18 |
| Short Interest | — | 52W High | 2.64 | 52W Low | 0.53 |
| Beta | 1.55 | Avg Volume | 4.25M | Volume | 14.94M |
| Target Price | $11.29 | Recom | Strong_buy | Prev Close | $1.78 |
| Price | $1.75 | Change | -1.69% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.29
Mean price target
2. Current target
$1.75
Latest analyst target
3. DCF / Fair value
$-0.64
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.75
Low
$5.00
High
$25.00
Mean
$11.29
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-26 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2026-02-25 | init | Stifel | — → Buy | $5 |
| 2026-01-09 | init | B. Riley Securities | — → Buy | $7 |
| 2025-12-30 | init | Clear Street | — → Buy | $12 |
| 2025-12-29 | init | Piper Sandler | — → Overweight | $25 |
| 2025-05-13 | main | Brookline Capital | Buy → Buy | $16 |
| 2024-11-20 | init | Brookline Capital | — → Buy | $38 |
| 2024-11-13 | main | Maxim Group | Buy → Buy | $8 |
| 2024-05-01 | reit | Maxim Group | Buy → Buy | $23 |
| 2024-04-16 | main | Maxim Group | Buy → Buy | $23 |
| 2023-11-17 | up | Maxim Group | Hold → Buy | $2 |
| 2023-05-16 | main | Ladenburg Thalmann | Buy → Buy | $16 |
| 2023-03-30 | up | Maxim Group | Hold → Buy | $50 |
- $PALI stock is down 11% today. Here's what we see in our data. - Quiver Quantitative Mon, 30 Mar 2026 14
- Palisade Bio posts trial data for lead asset (PALI:NASDAQ) - Seeking Alpha ue, 31 Mar 2026 17
- After 2 weeks, Palisade’s Crohn’s pill showed no serious side effects - Stock Titan Mon, 30 Mar 2026 20
- Clear Street reiterates Palisade Bio stock rating on trial data - Investing.com ue, 31 Mar 2026 21
- Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease - marketscreener.com ue, 31 Mar 2026 18
- All You Need to Know About Palisade Bio (PALI) Rating Upgrade to Buy - Yahoo Finance hu, 06 Nov 2025 08
- Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Rises By 20.2% - MarketBeat Wed, 04 Mar 2026 08
- Latest PALI News - Palisade Bio Announces Participation in Two... - Stock Titan Fri, 16 Jan 2026 08
- Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher - Yahoo Finance Mon, 10 Nov 2025 08
- Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock By Investing.com - Investing.com South Africa Sat, 14 Feb 2026 08
- Palisade Bio leaders set for virtual Oppenheimer healthcare conference slot - Stock Titan hu, 05 Feb 2026 08
- $PALI stock is down 8% today. Here's what we see in our data. | PALI Stock News - Quiver Quantitative hu, 15 Jan 2026 08
- Insiders own 42% of Palisades Goldcorp Ltd. (CVE:PALI) shares but retail investors control 56% of the company - Yahoo Finance Wed, 21 Jan 2026 08
- $138M Raised: Palisade Bio Closes Upsized Offering to Fund Phase 2 PALI-2108 - Stock Titan hu, 02 Oct 2025 07
- PALI SEC Filings - Palisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan Mon, 23 Mar 2026 20
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
0.25
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
0.25
|
0.00
|
| Operating Expense |
|
18.06
+21.52%
|
14.86
+13.47%
|
13.10
-14.47%
|
15.31
|
| Research And Development |
|
10.19
+12.46%
|
9.06
+31.48%
|
6.89
+5.28%
|
6.55
|
| Selling General And Administration |
|
7.86
+35.68%
|
5.80
-6.55%
|
6.20
-29.23%
|
8.76
|
| General And Administrative Expense |
|
7.86
+35.68%
|
5.80
-6.55%
|
6.20
-29.23%
|
8.76
|
| Other Gand A |
|
7.86
+35.68%
|
5.80
-6.55%
|
6.20
-29.23%
|
8.76
|
| Total Expenses |
|
18.06
+21.52%
|
14.86
+13.47%
|
13.10
-14.47%
|
15.31
|
| Operating Income |
|
-18.06
-21.52%
|
-14.86
-15.68%
|
-12.85
+16.11%
|
-15.31
|
| Total Operating Income As Reported |
|
-18.06
-21.52%
|
-14.86
-13.69%
|
-13.07
+16.86%
|
-15.72
|
| EBITDA |
|
-16.77
-16.26%
|
-14.42
-17.44%
|
-12.28
+13.78%
|
-14.24
|
| Normalized EBITDA |
|
-16.77
-16.26%
|
-14.42
-19.63%
|
-12.06
+5.25%
|
-12.72
|
| Reconciled Depreciation |
|
0.00
+0.00%
|
0.00
-25.00%
|
0.00
+33.33%
|
0.00
|
| EBIT |
|
-16.77
-16.26%
|
-14.43
-17.43%
|
-12.29
+13.77%
|
-14.25
|
| Total Unusual Items |
|
—
|
0.00
+100.00%
|
-0.23
+85.20%
|
-1.52
|
| Total Unusual Items Excluding Goodwill |
|
—
|
0.00
+100.00%
|
-0.23
+85.20%
|
-1.52
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-0.23
+45.12%
|
-0.41
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Restructuring And Mergern Acquisition |
|
—
|
0.00
-100.00%
|
0.23
-45.12%
|
0.41
|
| Net Income |
|
-16.78
-16.23%
|
-14.44
-17.38%
|
-12.30
+13.74%
|
-14.26
|
| Pretax Income |
|
-16.78
-16.23%
|
-14.44
-17.38%
|
-12.30
+13.74%
|
-14.26
|
| Net Non Operating Interest Income Expense |
|
-0.01
+16.67%
|
-0.01
+20.00%
|
-0.01
-15.38%
|
-0.01
|
| Interest Expense Non Operating |
|
0.01
-16.67%
|
0.01
-20.00%
|
0.01
+15.38%
|
0.01
|
| Net Interest Income |
|
-0.01
+16.67%
|
-0.01
+20.00%
|
-0.01
-15.38%
|
-0.01
|
| Interest Expense |
|
0.01
-16.67%
|
0.01
-20.00%
|
0.01
+15.38%
|
0.01
|
| Other Income Expense |
|
1.28
+196.77%
|
0.43
-22.68%
|
0.56
-47.37%
|
1.06
|
| Other Non Operating Income Expenses |
|
1.28
+196.77%
|
0.43
-44.84%
|
0.79
-69.62%
|
2.58
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
-1.11
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-16.78
-16.23%
|
-14.44
-17.38%
|
-12.30
+13.74%
|
-14.26
|
| Net Income From Continuing Operation Net Minority Interest |
|
-16.78
-16.23%
|
-14.44
-17.38%
|
-12.30
+13.74%
|
-14.26
|
| Net Income From Continuing And Discontinued Operation |
|
-16.78
-16.23%
|
-14.44
-17.38%
|
-12.30
+13.74%
|
-14.26
|
| Net Income Continuous Operations |
|
-16.78
-16.23%
|
-14.44
-17.38%
|
-12.30
+13.74%
|
-14.26
|
| Normalized Income |
|
-16.78
-16.23%
|
-14.44
-19.57%
|
-12.07
+5.22%
|
-12.74
|
| Net Income Common Stockholders |
|
-16.78
-16.23%
|
-14.44
-17.23%
|
-12.32
+15.34%
|
-14.55
|
| Otherunder Preferred Stock Dividend |
|
—
|
0.00
-100.00%
|
0.02
-94.44%
|
0.29
|
| Diluted EPS |
|
-0.30
+97.06%
|
-10.19
+62.27%
|
-27.01
+89.11%
|
-247.95
|
| Basic EPS |
|
-0.30
+97.06%
|
-10.19
+62.27%
|
-27.01
+89.11%
|
-247.95
|
| Basic Average Shares |
|
55.67
+3830.18%
|
1.42
+210.62%
|
0.46
+677.03%
|
0.06
|
| Diluted Average Shares |
|
55.67
+3830.18%
|
1.42
+210.62%
|
0.46
+677.03%
|
0.06
|
| Diluted NI Availto Com Stockholders |
|
-16.78
-16.23%
|
-14.44
-17.23%
|
-12.32
+15.34%
|
-14.55
|
| Average Dilution Earnings |
|
—
|
—
|
—
|
0.00
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Assets |
|
14.05
-10.85%
|
15.76
|
—
|
| Current Assets |
|
13.33
-9.54%
|
14.73
|
—
|
| Cash Cash Equivalents And Short Term Investments |
|
12.43
+0.40%
|
12.38
|
—
|
| Cash And Cash Equivalents |
|
12.43
+0.40%
|
12.38
|
—
|
| Receivables |
|
0.15
-89.71%
|
1.44
|
—
|
| Accounts Receivable |
|
—
|
—
|
0.00
|
| Other Receivables |
|
0.15
-89.71%
|
1.44
|
—
|
| Prepaid Assets |
|
0.64
-20.30%
|
0.80
|
—
|
| Current Deferred Assets |
|
0.11
-1.75%
|
0.11
|
—
|
| Total Non Current Assets |
|
0.72
-29.71%
|
1.03
|
—
|
| Net PPE |
|
0.21
-32.90%
|
0.31
|
—
|
| Gross PPE |
|
0.21
-32.90%
|
0.31
|
—
|
| Properties |
|
0.00
|
0.00
|
—
|
| Buildings And Improvements |
|
0.20
-34.00%
|
0.30
|
—
|
| Machinery Furniture Equipment |
|
—
|
—
|
0.00
|
| Other Properties |
|
0.01
+0.00%
|
0.01
+233.33%
|
0.00
|
| Non Current Deferred Assets |
|
—
|
—
|
0.00
|
| Non Current Prepaid Assets |
|
0.48
-29.91%
|
0.68
-21.43%
|
0.87
|
| Other Non Current Assets |
|
0.04
+0.00%
|
0.04
|
—
|
| Total Liabilities Net Minority Interest |
|
2.74
-16.60%
|
3.28
|
—
|
| Current Liabilities |
|
2.59
-14.14%
|
3.01
|
—
|
| Payables And Accrued Expenses |
|
1.40
-35.07%
|
2.15
|
—
|
| Payables |
|
0.84
-53.83%
|
1.83
|
—
|
| Accounts Payable |
|
0.84
-53.83%
|
1.83
|
—
|
| Current Accrued Expenses |
|
0.55
+70.46%
|
0.33
|
—
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.91
+36.49%
|
0.67
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.28
+44.56%
|
0.19
|
—
|
| Current Debt |
|
0.16
+79.55%
|
0.09
|
—
|
| Other Current Borrowings |
|
0.16
+79.55%
|
0.09
|
—
|
| Current Capital Lease Obligation |
|
0.12
+15.24%
|
0.10
|
—
|
| Other Current Liabilities |
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.15
-43.75%
|
0.27
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
0.09
-57.35%
|
0.21
|
0.00
|
| Long Term Capital Lease Obligation |
|
0.09
-57.35%
|
0.21
|
0.00
|
| Other Non Current Liabilities |
|
0.06
+0.00%
|
0.06
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
0.00
|
| Stockholders Equity |
|
11.31
-9.34%
|
12.48
|
—
|
| Common Stock Equity |
|
11.31
-9.35%
|
12.48
|
—
|
| Capital Stock |
|
0.01
-75.00%
|
0.03
|
—
|
| Common Stock |
|
0.01
-80.00%
|
0.03
|
—
|
| Preferred Stock |
|
0.00
+0.00%
|
0.00
|
—
|
| Share Issued |
|
0.82
+106.43%
|
0.40
|
—
|
| Ordinary Shares Number |
|
0.82
+106.43%
|
0.40
|
—
|
| Additional Paid In Capital |
|
132.81
+9.19%
|
121.64
|
—
|
| Retained Earnings |
|
-121.51
-11.28%
|
-109.19
|
—
|
| Total Equity Gross Minority Interest |
|
11.31
-9.34%
|
12.48
|
—
|
| Total Capitalization |
|
11.31
-9.34%
|
12.48
|
—
|
| Working Capital |
|
10.74
-8.35%
|
11.72
|
—
|
| Invested Capital |
|
11.47
-8.72%
|
12.56
|
—
|
| Total Debt |
|
0.37
-8.66%
|
0.40
|
—
|
| Capital Lease Obligations |
|
0.21
-33.23%
|
0.32
|
—
|
| Net Tangible Assets |
|
11.31
-9.34%
|
12.48
|
—
|
| Tangible Book Value |
|
11.31
-9.35%
|
12.48
|
—
|
| Derivative Product Liabilities |
|
0.00
-96.72%
|
0.06
|
—
|
| Preferred Shares Number |
|
0.20
+0.00%
|
0.20
+0.00%
|
0.20
|
| Preferred Stock Equity |
|
0.00
+0.00%
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-10.85
+11.04%
|
-12.19
-9.52%
|
-11.13
+16.67%
|
-13.36
|
| Cash Flow From Continuing Operating Activities |
|
-10.85
+11.04%
|
-12.19
-9.52%
|
-11.13
+16.67%
|
-13.36
|
| Net Income From Continuing Operations |
|
-16.78
-16.23%
|
-14.44
-17.38%
|
-12.30
+13.74%
|
-14.26
|
| Depreciation Amortization Depletion |
|
0.00
+0.00%
|
0.00
-25.00%
|
0.00
+33.33%
|
0.00
|
| Depreciation |
|
0.00
+0.00%
|
0.00
-25.00%
|
0.00
+33.33%
|
0.00
|
| Depreciation And Amortization |
|
0.00
+0.00%
|
0.00
-25.00%
|
0.00
+33.33%
|
0.00
|
| Other Non Cash Items |
|
-0.09
-134.94%
|
0.25
+4250.00%
|
-0.01
+91.30%
|
-0.07
|
| Stock Based Compensation |
|
3.96
+506.60%
|
0.65
+4.49%
|
0.62
-39.53%
|
1.03
|
| Asset Impairment Charge |
|
0.07
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
0.35
+798.00%
|
-0.05
-134.48%
|
0.14
+111.02%
|
-1.32
|
| Gain Loss On Investment Securities |
|
0.35
+746.30%
|
-0.05
-137.24%
|
0.14
+111.02%
|
-1.32
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.00
|
0.00
|
—
|
| Change In Working Capital |
|
1.64
+17.83%
|
1.39
+247.75%
|
0.40
-68.00%
|
1.25
|
| Change In Receivables |
|
—
|
—
|
—
|
0.00
|
| Change In Prepaid Assets |
|
0.53
-29.47%
|
0.75
+6.38%
|
0.70
-31.35%
|
1.03
|
| Change In Payables And Accrued Expense |
|
1.20
+57.48%
|
0.76
+481.00%
|
-0.20
-150.13%
|
0.40
|
| Change In Accrued Expense |
|
0.58
+1128.57%
|
-0.06
-119.18%
|
0.29
|
—
|
| Change In Payable |
|
0.62
-23.72%
|
0.82
+266.26%
|
-0.49
|
—
|
| Change In Account Payable |
|
0.62
-23.72%
|
0.82
+266.26%
|
-0.49
|
—
|
| Change In Other Working Capital |
|
—
|
—
|
0.29
+1268.00%
|
-0.03
|
| Change In Other Current Liabilities |
|
-0.09
+25.62%
|
-0.12
-15.24%
|
-0.10
+30.46%
|
-0.15
|
| Investing Cash Flow |
|
—
|
0.00
+100.00%
|
-0.00
+60.00%
|
-0.01
|
| Cash Flow From Continuing Investing Activities |
|
—
|
0.00
+100.00%
|
-0.00
+60.00%
|
-0.01
|
| Net PPE Purchase And Sale |
|
—
|
0.00
+100.00%
|
-0.00
+60.00%
|
-0.01
|
| Purchase Of PPE |
|
—
|
0.00
+100.00%
|
-0.00
+60.00%
|
-0.01
|
| Capital Expenditure |
|
—
|
—
|
-0.00
+60.00%
|
-0.01
|
| Net Business Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Business |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
134.44
+1303.05%
|
9.58
-14.34%
|
11.19
-26.69%
|
15.26
|
| Cash Flow From Continuing Financing Activities |
|
134.44
+1303.05%
|
9.58
-14.34%
|
11.19
-26.69%
|
15.26
|
| Net Issuance Payments Of Debt |
|
-0.32
+24.88%
|
-0.43
-8.95%
|
-0.39
+50.51%
|
-0.79
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
-0.32
+24.88%
|
-0.43
-8.95%
|
-0.39
+50.51%
|
-0.79
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
-0.79
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
-0.79
|
| Short Term Debt Payments |
|
-0.32
+24.88%
|
-0.43
-8.95%
|
-0.39
+50.51%
|
-0.79
|
| Net Short Term Debt Issuance |
|
-0.32
+24.88%
|
-0.43
-8.95%
|
-0.39
+50.51%
|
-0.79
|
| Net Common Stock Issuance |
|
128.22
+1420.08%
|
8.44
-10.45%
|
9.42
-34.59%
|
14.40
|
| Proceeds From Stock Option Exercised |
|
7.65
+204.09%
|
2.52
-9.30%
|
2.77
+22.03%
|
2.27
|
| Net Other Financing Charges |
|
-1.11
-17.90%
|
-0.94
-53.00%
|
-0.62
+1.59%
|
-0.63
|
| Changes In Cash |
|
123.59
+4833.55%
|
-2.61
-5428.57%
|
0.05
-97.40%
|
1.89
|
| Beginning Cash Position |
|
9.85
-20.96%
|
12.46
+0.39%
|
12.41
+17.95%
|
10.52
|
| End Cash Position |
|
133.44
+1255.13%
|
9.85
-20.96%
|
12.46
+0.39%
|
12.41
|
| Free Cash Flow |
|
-10.85
+11.04%
|
-12.19
-9.48%
|
-11.14
+16.70%
|
-13.37
|
| Interest Paid Supplemental Data |
|
0.01
-28.57%
|
0.01
+0.00%
|
0.01
+16.67%
|
0.01
|
| Common Stock Issuance |
|
128.22
+1420.08%
|
8.44
-10.45%
|
9.42
-34.59%
|
14.40
|
| Issuance Of Capital Stock |
|
128.22
+1420.08%
|
8.44
-10.45%
|
9.42
-34.59%
|
14.40
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Sale Of Business |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-20 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-11 View
- 42026-02-11 View
- 42026-01-21 View
- 42026-01-13 View
- 8-K2025-12-04 View
- 10-Q2025-11-10 View
- 8-K2025-10-22 View
- 8-K2025-10-20 View
- 8-K2025-10-16 View
- 8-K2025-10-09 View
- 42025-10-08 View
- 42025-10-08 View
- 42025-10-08 View
- 42025-10-08 View
- 42025-10-08 View
- 8-K2025-09-26 View
- 8-K2025-09-18 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|